Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Sage Therapeutics (SAGE) PT Lowered to $90 at Wedbush, Following Earnings
May 4, 2021 11:32 AM EDTWedbush analyst Laura Chico lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $90.00 (from $98.00) while maintaining a Outperform rating.
... MoreSage Therapeutics (SAGE) PT Raised to $189 at Goldman Sachs, Following Earnings
May 4, 2021 11:11 AM EDTGoldman Sachs analyst Salveen Richter raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $189.00 (from $187.00) while maintaining a Buy rating.
... MoreSAGE Therapeutics (SAGE) Tops Q1 EPS by 27c, Revenues Miss
May 4, 2021 7:16 AM EDTSAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.64), $0.27 better than the analyst estimate of ($1.91). Revenue for the quarter came in at $1.58 million versus the consensus estimate of $2 million.
Sage started 2021 with significant advances across our depression, neurology and neuropsychiatry franchises,... More
